SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the crypto community debates its short-term trajectory, with some anticipating a continued climb towards new highs fueled by bullish technical indicators like double bottom formations on the 20-week EMA and institutions reporting even more ownership after buying OTC. Others remain cautious, citing potential weekend bull traps and the possibility of a pullback to lower support levels, sparking discussions on market manipulation and the influence of major players like Michael Saylor.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community rallies around the meme-based token on the Solana network. Community members are actively sharing the token's contract address and encouraging others to swap $SOL for $UPDOG on $JUP.X. The coin has been live for over a year and the community is constantly asking each other the age old question, 'What's UpDog?'

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is experiencing heightened interest, possibly due to its privacy features and upcoming halving event, with some community members drawing comparisons to Bitcoin's early days and anticipating significant price appreciation. Community discussions revolve around price targets and the potential for Zcash to outperform other cryptocurrencies. Zcash's focus on shielded transactions is also seen as a key differentiator in a world increasingly concerned about financial privacy.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as community members discuss potential partnerships, including speculation around Apple and TSMC, and the impact of government investment in domestic chip manufacturing. Bullish sentiment is fueled by the possibility of Intel becoming a key player in the U.S. semiconductor industry. Some traders are also discussing short positions and potential pullbacks after the recent price increase.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as community members discuss Cigna adding Auvelity to its preferred drug list in 2026, potentially setting a precedent for other insurers. Sponsorship of educational events and analysis of prescription data are also fueling conversation. Despite some concerns regarding share sales and pipeline candidates, many remain optimistic about Axsome's growth trajectory and potential FDA approvals.

JFB Construction Holdings is a commercial and residential real estate construction and development company, which engages in delivering services to commercial and residential markets. It operates through the following segments: Commercial Construction, Residential Construction, and Real Estate Development. The Commercial Construction segment includes all activities related to the construction of commercial properties. The Residential Construction segment focuses on the construction of residential properties including single-family homes and multi-family units. The Real Estate Development segment refers to the acquisition, development, and sale of real estate properties. The company was founded by Joseph F. Basille III on April 9, 2024 and is headquartered in Lantana, FL.

JFB Construction Holdings - Ordinary Shares - Class A

JFB is trending due to a recently announced $44 million private placement, sparking significant after-hours trading activity. The community is actively discussing the potential impact of the financing on the company's growth and balance sheet, while also considering the stock's tight float and potential for continued momentum.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics is trending after releasing Phase 3 trial data for their skin drug, sonelokimab, which showed mixed results and a higher-than-expected placebo response in one study. While some view the data as disappointing, others speculate on a potential buyout and future gains, leading to active discussions about the drug's efficacy and market potential. The community is also closely watching for potential short squeezes and overnight trading activity.

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

Uranium Energy Corp

Uranium Energy Corp is trending amid bullish sentiment surrounding nuclear energy and discussions of potential policy tailwinds. Community members are actively discussing entry points, price targets, and the company's potential to benefit from increased demand driven by AI and data centers. Some traders are also noting unusual options activity and technical patterns, while others debate the company's valuation and production capabilities relative to its peers.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies is trending due to community excitement surrounding its Nasdaq uplisting and potential exposure to a broader investor base. Discussions revolve around the company's focus on post-quantum cryptography and its potential role in securing digital assets, with some anticipating significant growth and institutional interest. Some investors are concerned about potential dilution following the uplisting.

Amplify ETF Trust - Amplify Alternative Harvest ETF

ETF Managers Group LLC - ETFMG Alternative Harvest ETF

The ETFMG Alternative Harvest ETF ($MJ) is trending amid discussions surrounding potential marijuana reclassification and legalization, spurred by comments from political figures like Trump. Community members are weighing the potential impact of rescheduling on the sector and debating whether it will truly spark a sustained rally, while some express frustration over long-term losses and dilution.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?

Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.

Atara Biotherapeutics (ATRA) Soars 10.0%: Is Further Upside Left in the Stock?

Atara Biotherapeutics (ATRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength?

Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy?

Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 138.2% in Amicus Therapeutics (FOLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales

Amicus misses second-quarter earnings estimates but beats the same for revenues, driven by strong sales of Galafold and Pombiliti + Opfolda.

Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates

Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -50.00% and +4.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Moderna (MRNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for June 3rd 

Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Amicus Therapeutics Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

Current Price	$8.24
Prev Close	$8.32
Open	$8.35
Dividend Yield	0.00%
50-Day Moving Average	$7.32
Beta	0.88
Avg. Volume	4.06M
PE Ratio	-67.27

52-Week High	$12.65
52-Week Low	$5.51
Market Capitalization	$2.54B
EPS (Annual)	-$0.1843
Price to Book	12.42
Revenue Per Employee	$1.06M
Enterprise Value/EBITDA	N/A

FOLD
Amicus Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FOLD News

FOLD Amicus Therapeutics Inc